<DOC>
	<DOCNO>NCT00776984</DOCNO>
	<brief_summary>The trial randomise , double-blind , placebo-controlled , parallel-group trial evaluate efficacy safety 5 µg tiotropium 48-week treatment period compare placebo . Tiotropium inhalation solution deliver Respimat® inhaler examine add-on controller therapy top usual care patient severe persistent asthma . The primary objective trial evaluate long term efficacy tiotropium placebo top usual care patient severe persistent asthma determine pulmonary function testing , effect asthma exacerbation , effect quality life , asthma control health care resource utilisation . The secondary objective trial compare long term safety tiotropium placebo patient population .</brief_summary>
	<brief_title>Evaluation Tiotropium 5 µg/Day Delivered Via Respimat® Inhaler Over 48 Weeks Patients With Severe Persistent Asthma Top Usual Care ( Study II )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign date Informed Consent Form consistent ICHGCP guideline local legislation prior participation trial ( i.e . prior trial procedure , include pretrial washout medication medication restriction pulmonary function test Visit 1 ) . 2 . Male female patient age least 18 year 75 year . 3 . All patient must least 5year history asthma time enrolment trial diagnosis asthma must make patient´s age 40 . 4 . All patient must diagnosis severe persistent asthma must symptomatic despite treatment high , stable dos inhaled corticosteroid longacting beta adrenergic agent 5 . All patient must history one asthma exacerbation past year . 6 . Patients must evidence treat , severe , persistent asthma postbronchodilator pulmonary function test . 7 . Patients neversmokers exsmokers stop smoke least one year prior enrolment smoke history le 10 pack year 8 . Patients must able use Respimat® inhaler correctly 9 . Patients must able perform trial related procedure include technically acceptable pulmonary function test use electronic diary/peak flow meter . Exclusion criterion : 1 . Patients significant disease asthma . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient´s ability participate trial . 2 . Patients clinically relevant abnormal screen haematology blood chemistry . 3 . Patients recent history ( i.e . six month less ) myocardial infarction , hospitalisation cardiac failure past year , unstable life threaten cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year , know active tuberculosis , malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( treat basal cell carcinoma allow ) , lung disease asthma ( e.g . COPD ) , significant alcohol drug abuse within past two year , patient undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 . 4 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior screen visit ( Visit 1 ) . 5 . Patients use oral corticosteroid medication stable dos exceed 5 mg prednisolone prednisolone equivalent every day 10 mg prednisolone prednisolone equivalent every second day . 6 . Patients know hypersensitivity anticholinergic drug , BAC , EDTA components tiotropium inhalation solution . 7 . Pregnant nursing woman woman childbearing potential use highly effective method birth control . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation/salpingectomy , postmenopausal least two year . 8 . Patients take investigational drug within four week six halflives ( whichever great ) prior Visit 1 . 9 . Patients treat longacting anticholinergic tiotropium ( Spiriva® ) , betablocker medication , oral betaadrenergics , nonapproved accord international guideline recommend ´experimental´ drug routine asthma therapy ( e.g . TNFalpha blocker , methotrexate , cyclosporin ) within four week prior Screening Visit ( Visit 1 ) screening period . 10 . Patients asthma exacerbation respiratory tract infection four week prior trial . 11 . Patients previously randomise trial respective twin trial ( 205.416 versus 205.417 ) currently participate another trial . 12 . Patients know narrowangle glaucoma . Note : As anticholinergic drug , tiotropium use caution patient prostatic hyperplasia bladder neck obstruction . As predominantly renally excrete drug , patient moderate severe renal impairment ( know creatinine clearance &lt; = 50 mL/min ) treat tiotropium monitor closely .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>